The stock of Regenxbio Inc (NASDAQ:RGNX) registered a decrease of 11.37% in short interest. RGNX’s total short interest was 2.17M shares in January as published by FINRA. Its down 11.37% from 2.45 million shares, reported previously. With 468,300 shares average volume, it will take short sellers 5 days to cover their RGNX’s short positions. The short interest to Regenxbio Inc’s float is 7.8%.

The stock decreased 1.97% or $0.92 during the last trading session, reaching $45.78. About 142,372 shares traded. REGENXBIO Inc. (NASDAQ:RGNX) has risen 75.68% since January 10, 2018 and is uptrending. It has outperformed by 75.68% the S&P500.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $1.64 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It has a 19.93 P/E ratio. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

More notable recent REGENXBIO Inc. (NASDAQ:RGNX) news were published by: which released: “REGENXBIO: An Underappreciated Leader In Gene Editing – Seeking Alpha” on April 21, 2018, also with their article: “Healthcare: 2 Hot Biotech Stocks on Our Radar – The Motley Fool” published on September 28, 2018, published: “REGENXBIO’s (RGNX) CEO Ken Mills on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 07, 2018. More interesting news about REGENXBIO Inc. (NASDAQ:RGNX) were released by: and their article: “Regenxbio (RGNX) Announced $100M Accelerated License Payment from Novartis –” published on June 11, 2018 as well as‘s news article titled: “Regenxbio Part I: A Novel Gene Therapy Innovator With Substantial Unlocked Value – Seeking Alpha” with publication date: March 11, 2018.


– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *